In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, discusses the need for change in the clinical research industry and how the adoption of new technology can increase operational ...
Ron Lanton, Partner, Lanton Law, shares his insights on the legal and political consequences of the NIH funding freeze and potential options for continuing research.
In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, highlights the need for a satellite model in bringing clinical trials to more rural locations.
Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Symbravo Outperforms Oral CGRP Inhibitors in Phase III Trial, With Faster, Sustained Migraine Relief
Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...
In this video interview, Pomerantseva, director of product management, RBQM, eClinical Solutions, discusses the new guidance ...
Ron Lanton, Partner, Lanton Law, discusses how stakeholders must navigate funding future clinical research amid NIH budget cuts.
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest ...
Beyond direct costs, CROs incur significant expenses in the pre-award phase, creating strategic proposals to compete for trial contracts from sponsors. These activities, often unpaid, cost millions ...
External control arms, as an integral part of clinical development, present many potential opportunities for sponsors and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback